Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study by Goessens, Laurent et al.
Received: 28 July 2021 - Accepted: 22 September 2021DOI: 10.1002/ueg2.12170
O R I G I N A L A R T I C L E
Safety and efficacy of combining biologics or small molecules
for inflammatory bowel disease or immune‐mediated
inflammatory diseases: A European retrospective
observational study
Laurent Goessens1 | Jean‐Frédéric Colombel2 | An Outtier3 | Marc Ferrante3 |
Joao Sabino3 | Ciaran Judge4 | Reza Saeidi5 | Louise Rabbitt6 |
Alessandro Armuzzi7 | Eugeni Domenech8 | George Michalopoulos9 |
Anneline Cremer10 | Francisco Javier García‐Alonso11 | Tamas Molnar12 |
Konstantinos Karmiris13 | Krisztina Gecse14 | Joep Van Oostrom14 |
Mark Löwenberg14 | Klaudia Farkas12 | Raja Atreya15 |
Davide Giuseppe Ribaldone16 | Christian Selinger17 | Frank Hoentjen18 |
Benoit Bihin19 | Shaji Sebastian20 | European COMBIO study group |
Jean‐François Rahier1
1Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire UCL Namur, Yvoir, Belgium
2Icahn School of Medicine at Mount Sinai, New York, New York, USA
3Department of Gastroenterology and Hepatology, KU Leuven, University Hospital Leuven, Leuven, Belgium
4Department of Gastroenterology, INITIative IBD Research Network, Mercy University Hospital, Cork, Ireland
5Centre for Colorectal Disease, INITIative IBD Research Network, St Vincent’s University Hospital & School of Medicine, University College Dublin, Dublin, Ireland
6Department of Clinical Pharmacology and Therapeutics, INITIative IBD research network, Galway University Hospital, Galway, Ireland
7IBD Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
8Gastroenterology Department, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, Hospital Universitari Germans Trias i Pujol,
Badalona, Spain
9Gastroenterology Department, General Hospital of Piraeus ‘Tzaneio’, Piraeus, Greece
10Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
11Gastroenterology Department, Hospital Universitario Rio Hortega, Valladolid, Spain
12Gastroenterology Unit, First Department of Medicine, University of Szeged, Szeged, Hungary
13Department of Gastroenterology, Venizeleio General Hospital, Heraklion, Greece
Conference presentation: Poster presentation at ECCO Congress February 2020, Vienna, Austria; Oral Abstract presentation at Belgian Week of Gastroenterology March 2020, Antwerp,
Belgium.
European COMBIO study group: Filip Baert, Shomron Ben Horin, Peter Bossuyt, Eduard Brunet Mas, Martin Buckley, Clodagh Byron, Carolann Coe, Glen A Doherty, Gabriele Dragoni, Samuel
Fernandes, Daniel P. Gaya, Sarah Gleeson, Aine Keogh, Arie Levine, Triana Lobaton Ortega, Alan J. Lobo, Elisabeth Macken, Jane McCarthy, Nurulamin Noor, Aoibhlinn O'Toole, Annelies Posen,
Giuseppe Privitera, Daniele Pugliese, Tim Raine, Catherine Reenaers, Tamas Resal, Antonella Scarcelli, Eoin Slattery, Beatrijs Strubbe, Kathleen Sugrue, Maarten Te Groen, Gisela Torres
Vicente, Marie Truyens, Anna Viola, Henit Yanai, Syed Akbar Zulquernain.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
United European Gastroenterol J. 2021;1–12. wileyonlinelibrary.com/journal/ueg2 - 1
14Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands
15Department of Medicine 1, University Hospital Erlangen, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg, Erlangen, Germany
16Department of Medical Sciences, University of Turin, Turin, Italy
17Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
18Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands
19Department of Statistics, Centre Hospitalier Universitaire UCL Namur, Yvoir, Belgium
20Hull University Teaching Hospitals NHS Trust, Hull, UK
Correspondence
Jean‐François Rahier, Department of
Gastroenterology, Centre Hospitalier
Universitaire UCL Namur, Université
catholique de Louvain, Avenue Dr Gaston
Therasse 1, 5530 Yvoir, Belgium.
Email: jfrahier@gmail.com
Abstract
Background and aims: Few data are available regarding the combination of bi-
ologics or small molecules in inflammatory bowel disease (IBD) patients. We
report safety and efficacy of such combinations through a retrospective multi-
centre series.
Methods: Combination therapy was defined as the concomitant use of two biologics
or one biologic with a small molecule. Patient demographics, disease characteristics
and types of combinations were recorded. Safety was evaluated according to the
occurrence of serious infection, opportunistic infection, hospitalisation, life‐
threatening event, worsening of IBD or immune‐mediated inflammatory diseases
(IMID), cancer and death. Efficacy was evaluated as the physician global assessment
of the combination and comparison of clinical/endoscopic scores of IBD/IMID
activity prior and during combination.
Results: A total of 104 combinations were collected in 98 patients. Concomitant
IMID were present in 41 patients. Reasons for starting combination therapy were
active IBD (67%), active IMID or extra‐intestinal manifestations (EIM) (22%), both
(10%) and unclassified in 1. Median duration of combination was 8 months (inter-
quartile range 5–16). During 122 patient‐years of follow‐up, 42 significant adverse
events were observed, mostly related to uncontrolled IBD. There were 10 significant
infections, 1 skin cancer and no death. IBD disease activity was clinically improved in
70% and IMID/EIM activity in 81% of the patients. Overall, combination was
continued in 55% of the patients.
Conclusions: Combination of biologics and small molecules in patients with IBD and
IMID/EIM seems to be a promising therapeutic strategy but is also associated with a
risk of opportunistic infections or infections leading to hospitalisation in 10%.
K E Y W O R D S
biologics, combination therapy, immune mediated inflammatory disease, inflammatory bowel
disease, safety, small molecules, treatment
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory
bowel diseases (IBD) characterised by a widely variable clinical course
and heterogeneous presentations including extra‐intestinal manifes-
tations (EIM), mainly rheumatological and dermatological conditions.
Their association with other immune‐mediated inflammatory diseases
(IMID) is well known. Knowledge and treatments in IBD and other
IMIDs are continuously evolving and there is currently a broad rangeof
approved biologics and small molecules that target different inflam-
matory pathways.1 Despite the progress in therapeutic armamen-
tarium, it is still common to come across IBD patients with primary or
secondary loss of response to numerous medications or in whom EIM
are not properly controlled whilst the IBD is in remission.
In this setting, few clinical series reported efficacy and safety
outcomes of combining two biologics and/or small molecules in IBD
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patients. Although no new safety signals have been observed in
limited case series,2–9 questions have naturally arisen regarding po-
tential side effects. One recent meta‐analysis summarised the exist-
ing data on safety and efficacy of combining biologics and small
molecules. Ahmed et al.10 identified 279 patients in 30 studies and
reported an acceptable safety profile in these patients. Limitations of
the pooled analysis were the inconsistent definitions in reporting
patient outcomes for efficacy and safety and the significant hetero-
geneity of the different studies.
The major aim of this study was to determine the safety of
combining two biologics or one biologic and one small molecule. The
minor aim was to evaluate the therapeutic efficacy of combining
these treatments in different IBD and IMID scenarios.
MATERIALS AND METHODS
Study design and patient selection
This was a retrospective multicentre, European observational study.
The project received endorsement from the ECCO National Study
Group Committee in 2019 and 2020 (ECCO Congresses). Partici-
pating investigators were asked to screen their databases for a time
window of 3.5 years (starting from 1 November 2016 until 1 June
2020) to identify patients on combination eligible for the study.
Inclusion criteria were a diagnosis of CD, UC or IBD‐unclassified; age
>18 years and patients willing to sign an informed consent form.
Combination was defined as the concomitant use (from 1 day to no
limitation in duration) of a minimum of two biologics, or of one
biologic combined with one small molecule. Patients on combination
including a biologic or a small molecule approved for other IMIDS but
not yet for IBD were also included.
Patients were initiated on a second biologic or small molecule
(defined hereafter as the combination) for any of the following rea-
sons: (i) active IBD (group A), (ii) both active IBD and associated IMID
or EIM (group B) and (iii) active IMID or EIM despite quiescent IBD
(group C).
Data collection
Local investigators had access to all source documents and patients
were pseudo‐anonymised. An appropriate case report form (CRF)
was designed to collect in an homogeneous way disease character-
istics (IBD subtype, age on IBD diagnosis, disease duration, disease
classification, prior intestinal surgeries, EIM and past and ongoing
treatments), patient characteristics (year of birth, significant history
and comorbiditiesand associated IMID), characteristics of the com-
bination (type, order, doses and duration), evolution of IBD activity
under combination (clinical and endoscopic activity), inflammatory
markers (faecal calprotectin and C‐reactive protein [CRP]), clinical
evolution of IMID/EIM activity, global physician assessment of the
combination, need for surgery and corticosteroid use during
combination therapy. We also collected data on significant adverse
events (see below) during combination. The following data were also
recorded in a standardised way: start date for combination consid-
ered as the date when a biologic or a small molecule was added to an
existing treatment (biologic or small molecule); indication for com-
bination; dates and reasons for stopping the combination. Treat-
ments used for combination were classified into five categories: anti‐
TNF therapies (infliximab, adalimumab, certolizumab, golimumab and
etanercept); anti‐integrin therapy (vedolizumab); anti‐interleukin
therapies directed against interleukin 4/13, 5, 6, 12/23, 17A and 23
(dupilumab, mepolizumab, tocilizumab, ustekinumab, secukinumab
and risankizumab); JAK inhibitor (tofacitinib); and other small mole-
cules (apremilast, ciclosporine, leflunomide and tacrolimus).
Outcomes
The primary outcome measure was safety of the combination ac-
cording to the occurrence of any significant adverse events and
defined as (i) serious infection leading to hospitalisation, (ii) oppor-
tunistic infection, (iii) hospitalisation or prolonged hospitalisation for
any reason, (iv) life‐threatening event, (v) event resulting in persis-
tent or significant disability/incapacity, (vi) aggravation of IBD or
IMID, (vii) recurrent cancer or new incident cancer and (viii) death.
Adverse events were graded from 1 to 5 according to the Common
Terminology Criteria for Adverse Events: Grade 1: asymptomatic or
Key summary
Summarise the established knowledge on this subject
� Questions have arisen regarding potential side effects of
combining biologics together or with small molecules.
� No new safety signals have been observed in limited case
series.
� Partial efficacy have been shown in limited case series.
What are the significant and/or new findings of this study?
� When the combination was initiated for active inflam-
matory bowel disease (IBD), clinical and endoscopic
improvement is observed in more than half of the
patients.
� Treatment of immune‐mediated inflammatory disease
(IMID)/extra‐intestinal manifestations (EIM) manifesta-
tions by combining biologics was successful showing that
this strategy is realistic and useful in IBD patients with
uncontrolled IMID/EIM.
� 10% of the patients presented with one opportunistic
infection or an infection leading to hospitalisation indi-
cating that infectious complications remain the main
concern of this approach.
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mild symptoms; clinical or diagnostic observations only; no inter-
vention indicated. Grade 2: moderate, minimal, local or non‐invasive
intervention indicated; limiting age‐appropriate instrumental ADL
(activities of daily living). Grade 3: severe or medically significant but
not immediately life‐threatening; hospitalisation or prolongation of
hospitalisation indicated; disabling; limiting self‐care ADL. Grade 4:
life‐threatening consequences; urgent intervention indicated. Grade
5: death related to an adverse event.
Secondary outcomes were therapeutic efficacy and persistence
of such combinations, evaluated as follows: (i) IBD/IMID disease
activity during combination based on physician global assessment
using a 5‐point Likert scale: complete improvement, partial
improvement, situation stable/unchanged, worsening after initial
improvement and worsening; (ii) comparison of simple clinical (for
IBD, for IMID or EIM) and endoscopic (for IBD) activity scores
(quiescent scores 0 point, mild scores 1, moderate scores 2 and
severe scores 3) prior to and during combination. The same scores
were used numerically to evaluate the mean clinical and endoscopic
activity as well as their evolution under combination therapy.
Clinical assessment was done immediately before the start of the
combination whilst a time window of maximum 4 months prior to
the combination was accepted for endoscopic assessment. There
were no predefined time points for clinical and endoscopic evalua-
tion during combination, so the latest information available in the
medical file was retrieved; (iii) time on combination therapy (per-
centage of patients still on combination therapy after 6 and
12 months).
Statistical analysis
All statistical analyses were performed using R‐3.6.0 (The R Foun-
dation for Statistical Computing, Austria, Vienna, 2019). Continuous
variables were presented as mean � standard deviation or median
and interquartile range (IQR), as appropriate, whereas categorical
variables were presented as numbers and proportions or frequencies.
For efficacy analysis, variables before and after intervention were
compared using paired t‐test or Wilcoxon signed‐rank test for
continuous variables. Statistically significant difference was defined
as a two‐tailed p < 0.05 for all tests. Time spent on combination was
estimated by the Kaplan–Meier method.
Ethical considerations
Study protocol and materials were approved by the institutional
review boards at CHU UCL Namur University Hospital, Yvoir,
Belgium, Central Ethic Committee Mont‐Godinne 174/2019 ‘the
COMBIO – BIRD2019001’: final acceptance 7 July 2020. The trial
was conducted in compliance with the principles of the Declaration
of Helsinki, the principles of GCP and in accordance with all
applicable regulatory requirements. The protocol and related doc-
uments were submitted for review and accepted by Ethics
Committees and local regulators from each participating site ac-
cording to their own legislation. The investigators and the
participating sites treated all information and data related to the
study disclosed to the participating sites and/or investigators in
this study as confidential and did not disclose such information to
any third parties or use such information for any purpose other
than the performance of the study. The collection, processing and
disclosure of personal data, such as patient health and medical
information were subject to compliance with applicable personal
data protection and the processing of personal data. (General Data
Protection Regulation and Belgian Law of 30 July 2018 on the
protection of natural persons with regard to the processing of
their personal data).
RESULTS
Patients and baseline characteristics
A total of 130 CRF were received. Of these 21 were not analysed
because the start date of combination was after the deadline
mentioned in the protocol and five due to incomplete data. A total
of 104 combinations were identified in 98 IBD patients (6 patients
received more than one different combination after failing a first
combination). Preliminary data from 27 patients have already been
previously reported.4,9 The baseline characteristics of patients are
shown in Table 1. The vast majority of patients attended academic
centres for their IBD care (88%). The median age at diagnosis was
26 years (IQR 18–37), majority were women (56%) and Caucasians
(94%). Median disease duration was 10 years (IQR 6–21) and all
patients had failed prior biologics with a median use of three
agents (IQR 3–4; Table S1). Concomitant IMID conditions or EIM
were present in 41 (42%) and 42 (43%) patients, respectively.
Patients were followed up (from the start date of combination
until the date of the last consultation) for a median time of
14.5 months (IQR 8–26).
Combination therapies
The type and indications for various combination are shown in
Table 2. The reason for combining was mostly identical to the
reason for introducing the second treatment but the indication
was sometimes double (i.e. partial control of IBD with the first
drug and uncontrolled IMID). Details on the type of combination,
order, indication and prior use of the second drug are shown in
Table S2. The most used combination was anti‐TNF and anti‐
integrin followed by anti‐IL23 and an anti‐integrin. Overall, 80%
of patients were naïve to the second drug introduced. Data on
dose intensification was available for 96% of all combinations: 29%
had one drug dose intensified (first or second) and 13% had both
drugs dose intensified. On initiation of combination, 14 (13%)
patients were receiving concomitant immunomodulators
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T A B L E 1 Baseline characteristics of patients and diseases
Patients characteristics All patients n = 98 CD n = 58 UC n = 40
Male sex (n, %) 43 (44) 26 (45) 17 (43)
Age at IBD diagnosis (median, [IQR]) 26 [18–37] 27 [17.25–34.75] 25.5 [19.75–41.25]
Montreal classification (n, %) L1: 10 (17)
L2: 11 (19) E1: 3 (8)
L3: 37 (64) E2: 13 (33)
L4: 4 (7) E3: 24 (60)
B1: 26 (45) S1: 2 (5)
B2: 17 (29) S2: 9 (23)
B3: 15 (26) S3: 26 (65)
P: 27 (47)
Tobacco use (n, %)
Active 12 (12) 11 (19) 1 (3)
Never or former 82 (84) 46 (79) 36 (90)
Unknown 4 (4) 1 (2) 3 (7)
Presence of EIM (n, %) 42 (43) 29 (50) 13 (33)
Type of EIM (n, %)
Osteoarticular 23 (55) 17 (59) 6 (46)
Skin 18 (43) 12 (41) 6 (46)
Liver 5 (12) 3 (10) 2 (15)
AI pancreatitis 1 (2) – 1 (8)
Ocular 10 (24) 5 (17) 5 (39)
Associated IMID (n, %) 41 (42) 26 (45) 15 (38)
Patients with >1 IMID (n, %) 9 (9) 6 (10) 3 (8)
Type of IMID (n, %)
Ankylosing spondylarthritis 25 (61) 18 (69) 7 (47)
Psoriasis 12 (29) 7 (27) 5 (33)
Psoriatic arthritis 4 (10) 2 (8) 2 (13)
Rheumatoid arthritis 4 (10) 2 (8) 2 (13)
Othersa 7 (17) 3 (12) 4 (27)
Patient with prior surgery for IBD (n, %) 39 (40) 38 (66) 1 (3)
Number of prior surgeries (median, IQR) 2 [1–3] 2 [1–3] 1 [1–1]
Number of prior biologics (median, [IQR]) 3 [3–4] 4 [3–5] 3 [3–4]
Number of prior immunomodulators (median, [IQR]) 2 [1–2] 2 [1–2] 1.5 [1–2]
History of cancerb (n, %) 4 (4) 4 (7) ‐
History of serious infectionc (n, %) 13 (13) 9 (16) 4 (10)
Significant co‐morbidities (n, %)
Cardiopulmonary 6 (6) 5 (9) 1 (3)
Othersd 11 (11) 6 (10) 5 (13)
aOther IMID: Generalised constitutional eczema and hyperIgE syndrome, haemolytic anaemia, asthma, morphea generalisata, iridocyclitis, lupus and
Takayasu’s arteritis.
bBreast cancer, hepatocarcinoma, melanoma and squamous cell cancer.
cLatent tuberculosis, fistulazing pretibial abcedation (pyoderma gangrenosum), perforated diverticulitis, ophthalmic zona, cutaneous zonas, perineal
abscess, sepsis (pulmonary, urinary and Clostridium), staphylococcemia, bronchopneumony, candidiasis, right ulnar osteitis and Clostridium difficile.
dDiabetes, interstitial nephritis, cerebrovascular ischaemia, adrenal deficiency, venous thrombosis, liver transplantation, paroxysmal nocturnal
haemoglobinuria and prothrombin mutation.
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(thiopurines, methotrexate or mycophenolate mofetil) and 34
(33%) were on concomitant systemic corticosteroids.
The median age at starting the combinations was 41 years (IQR
30.5–53.5). The median duration of combination was 8 months (IQR
5–16) for a total of 122 patient‐years. At the last follow‐up consul-
tation, 57 (55%) combinations were continuing whilst 47 (45%) had
been discontinued.
Safety analysis
Overall, 41 patients (42%) experienced a total of 42 significant
adverse events. Events were graded as Grade 1 (n = 2), Grade 2
(n = 8), Grade 3 (n = 17), Grade 4 (n = 3), Grade 5 (n = 0) and not
graded (n = 12). Serious infections leading to hospitalisation and/or
opportunistic infection were observed in 10 out of 98 patients and
T A B L E 2 Overview of classes and indications of combinations




(A) n = 70
Both active IBD and
active IMID/EIM (B) n = 10
Active IMID/EIM
(C) n = 23
Anti‐TNF + VZ 41 31 5 5
Anti‐TNF + anti‐IL 11 7 1 3
Anti‐IL + VZ 21 16 – 5
Tofacitinib + anti‐TNF 1 1 – –
Tofacitinib + VZ 13 10 2 1
Anti‐IL + anti‐IL 1 1 ‐ ‐
Combinations with other moleculesb 16a 4 2 9
Abbreviations: EIM, extra‐intestinal manifestation; IBD, Inflammatory bowel disease; IL, Interleukin; IMID, immune mediated inflammatory disease;
TNF, Tumour Necrosis Factor; VZ, vedolizumab.
aOne combination was Risankizumab + Tacrolimus for IBD and liver transplantation.
bApremilast, Ciclosporine, Rituximab, Leflunomide and Tacrolimus. Details of all the combinations is given in Supplementary Table S2.
T A B L E 3 Serious and opportunistic infection in patients on combinations
Serious and opportunistic
















Vedolizumab (ID) + Infliximab
(SD) + Azathioprine
No 26 3 Yes/No Possibly
related
Resolved





Adalimumab (ID) + Vedolizumab (SD) No 38 2 No/No Possibly
related
Resolved
Campylobacter colitis Adalimumab (SD) + Vedolizumab (SD) Yes 49 3 Yes/No Possibly
related
Resolved
Pneumonia Infliximab (SD) + Vedolizumab
(SD) + Methotrexate
No 40 2 No/No Possibly
related
Resolved
Herpetic meningoencephalitis Certolizumab (SD) + Vedolizumab
(SD) + Methotrexate
No 43 3 Yes/No Possibly
related
Resolved
Esophageal candidiasis Adalimumab (ID) + Ustekinumab (ID) Yes 60 1 No/No Possibly
related
Resolved





Vedolizumab (SD) + Ustekinumab
(SD) + Azathioprine
No 18 3 Yes/No Possibly
related
Resolved
Abbreviations: ICU: intensive care unit; NB: standard dose (SD) or increased dose (ID).
aEvents were graded from 1 (asymptomatic or mild symptoms) to 5 (death) according to the Common Terminology Criteria for Adverse Events.
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are summarised in Table 3. All patients with serious infections had
CD, 9 (90%) had an associated IMID/EIM (five ankylosing spondylitis)
and 60% were concomitantly treated either with steroids and/or
immunomodulators. The median age of patients with serious in-
fections was identical to those without infection (data not shown).
Whilst anti‐TNF was used in 57% of all combinations (59/104), all
infectious events except 1 (90%) occurred in the TNF‐combined
group.
One patient had two hospitalisations considered unrelated to
inflammatory disease or combination: the patient was admitted due
to atrial fibrillation and later he suffered from angiotensin converting
enzyme (ACE) induced angioedema. One patient was hospitalised for
flare of primary sclerosing cholangitis resolved without discontinuing
combination. Hospitalisation or prolonged hospitalisation for wors-
ening IBD and/or IBD surgery was observed in 11 combinations and
were considered unrelated to the combination. Six patients under-
went IBD‐related surgery.
Life‐threatening events were observed in two patients (ACE‐
induced angioedema and hypersensitivity reaction to infliximab)
whereas no event resulting in persistent or significant disability/in-
capacity was observed. Worsening of IBD and worsening of IMID/
EIM without hospitalisation was observed in 13 and 3 combinations,
respectively. One patient was diagnosed with a new incident benign
skin neoplasia (clear cell acanthoma). Recurrent cancer and death
were not observed.
Global evaluation of the combination strategy
Global physician assessment of the combination strategy was avail-
able for all patients. In patients receiving the combination for active
IBD (n = 80), complete or partial improvement was observed in
21/80 (26%) and 35/80 (44%), respectively. In patients receiving the
combination for active EIM or IMID (n = 33), a complete or partial
F I G U R E 1 Global evaluation of the combination strategy in all active inflammatory bowel disease and all immune mediated inflammatory
disease /extra‐intestinal manifestation patients.
T A B L E 4 Evolution of the combination based on the indication
Indicationa
All
Patients with active IBD
Patients with both active
IBD and active IMID/EIM Patient with active IMID/EIM
Group A Group B Group C
N = 104a N = 70 N = 10 N = 23
Total combo duration: 1467.5 months/104 combinations
Percentage of patients with ongoing/stopped combination at last visit (n, %)
Ongoing 57 (55) 41 (59) 6 (60) 10 (43)
Stopped 47 (45) 29 (41) 4 (40) 13 (57)
Percentage of patients on combination at 6 and 12 months among patients with documented follow‐up (n, %)
>6 months 69/91 (76) 45/60 (75) 8/9 (89) 15/21 (71)
>12 months 36/62 (58) 24/41 (59) 4/7 (57) 8/14 (57)
Abbreviations: EIM, extra‐intestinal manifestation; IBD, Inflammatory bowel disease; IMID, immune mediated inflammatory disease.
aOne combination Risankizumab + Tacrolimus for IBD and liver transplantation.
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improvement was observed in 12/33 (36%) and 15/33 (45%),
respectively (Figure 1).
Table 4 gives the evolution of the combinations over time. The
median time to discontinuation of combination, estimated by Kaplan–
Meier, was 18 months (Figure 2; 95% CI: 10 months – not observed).
Among 34 patients receiving corticosteroids at baseline, 58% were
able to reduce and/or discontinue steroids by the time of the last
follow‐up consultation. Of the 104 combinations, 47 (45%) were
discontinued for the following reasons: absence or loss of response
for IBD in 25 patients (53%), absence or loss of response for IMID/
EIM in 5 (11%), clinical improvement with step‐down strategy in 10
(21%), intolerance in 2 (4%), adverse event in 4 (8%) and patient
decision in 1 (2%).
Efficacy of combination therapy for active IBD
In patients with combination initiated for active IBD alone (Group A)
and active IBD + active IMID/EIM (Group B), therapeutic efficacy
was assessed clinically and endoscopically. The patients in Group A1
were a sub‐group of patients from Group A who were previously
exposed to the second drug (Table S2). Table 5 shows the disease
activity parameters of the different groups prior to and during
combination. Overall, the mean clinical disease activity for IBD
(Groups A + B; N = 80) was significantly higher prior to combination
than during combination (2.2 � 0.7 vs. 1.2 � 1.1; p < 0.0001). Among
patients treated for active IBD as a unique indication (Group A), 17
had previously been exposed to the second drug used during com-
bination therapy (Group A1) and had a partial or incomplete response
(primary or secondary failure) to that drug in the past. During com-
bination, the reduction of the clinical score did not differ for these
patients (Group A‐A1 (n = 53): −1.0 � 1.0 vs. Group A1 (n = 17):
−1.1 � 1.1; p = 0.94).
Endoscopic evaluation was performed in 67 patients at a median
time of 1 month (IQR 0.25–3.75) before starting combination and 39
patients received a follow up endoscopy at a median time of
11 months (IQR 6–20) after starting combination (Table 5). In CD, the
two most effective combinations (complete or partial improvement
obtained) were anti‐integrin + anti‐IL23 in 11/13 (85%) followed by
anti‐TNF + anti‐integrin in 16/25 (64%). In UC, chances of success
were best observed with anti‐TNF + anti‐integrin in 8/11 (73%) and
anti‐integrin + tofacitinib in 8/12 (67%).
Efficacy of combination therapies for active IMID/EIM
The combination was initiated for active IMID/EIM manifestations
irrespective of IBD activity in 33 patients and therapeutic efficacy
was clinically assessed (Table 6). Mean clinical disease activity for
IMID/EIM was significantly higher prior starting combination than
during combination (2.3 � 0.5 vs. 1 � 0.8; p < 0.0001).
DISCUSSION
We report the safety and efficacy of combining biologics and small
molecule therapies in a large European multicentre series of IBD
patients with concomitant IMID and/or EIM.
The major aim of this study was to evaluate the safety of using
two biologics or small molecule simultaneously. During 122 patient‐
years of combination, we observed 42 significant adverse events in
41 patients, most of them graded 2 or 3 according to the CTCAE
classification. No new safety signals were found and three events
were considered unrelated to inflammatory disease or combination.
Worsening of IBD/IMID or need for IBD related surgery was
expected in this refractory IBD population and should be considered
as the absence of response to a treatment more than a medical or
surgical complication of the combination. About 10% of our patients
presented with one opportunistic infection or an infection leading to
hospitalisation indicating a rate of significant infection of 8.2/100
patient‐years. All patients with infections received an anti‐TNF
combined with another biologic except for one patient. In line with
previous work,2 we found that a substantial number of these patients
were concomitantly on systemic corticosteroids (n = 2) or on
immunomodulatory treatment (n = 4). Interestingly, these infectious
events mainly occurred in patients with concomitant IMID/EIM. The
infectious risk with anti‐TNF combination therapy has also been re-
ported in smaller series.5 Although the patient populations differed
between our study and the work performed by Ford and colleagues,
combination of biologics appears to carry a higher risk than that
observed in anti‐TNF monotherapy.11 Some series have not reported
any infectious events,4 but the recent meta‐analysis of patients on
F I G U R E 2 Proportion of patients on combination using
Kaplan–Meier curves according to indication of combination. Group
A: active inflammatory bowel disease (IBD); Group B: both active
IBD and immune mediated inflammatory disease (IMID)/extra‐
intestinal manifestation (EIM); Group C: active IMID or EIM
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biologic combinations reported infectious complications in up to 19%
of the patients.10 However, we found that this number is difficult to
interpret owing to the large heterogeneity in the nomenclature of
infectious events. Similarly, studies evaluating the combination of
biologic therapy in rheumatological diseases have dictated some
safety concerns. However, most of these studies carrying a warning
message used rituximab, abatacept or biologics that are not used for
IBD treatment (i.e. anti‐IL1). The 4% of our population presented a
history of cancer prior to combination therapy and no recurrence
was observed after a median time of 14.5 months. One patient was
diagnosed with new incident benign skin neoplasia. Death was not
observed.
In terms of efficacy, we were able to consider the cohort sepa-
rately according to the indication for combination. Similar to other
published series, our IBD patients were young at diagnosis and had
received multiple lines of treatments.3,5 The majority of treatments
were implemented owing to the persistence of luminal disease ac-
tivity. Despite the severity of IBD, improvement in clinical and
endoscopic activity was observed during combination therapy in a
significant proportion of patients. Similar findings have been
observed in small cohorts.3,5,9 Like other groups, we have observed a
reduction in corticosteroid use.2,4,5 Interestingly, a subgroup of our
patients (Group A1) had previous exposure to the second drug
introduced for combination and overall, this group responded like
other patients naïve to the second drug. The same findings were
observed in a small group of refractory CD patients treated with
combination where prior exposure to the drug did not influence the
chance of endoscopic response during combination.3 Recycling
strategies have also been successful for patients who previously
experienced loss of response to an anti‐TNF agent.12 In 33 out of 104
combinations, the indication was the control of EIM or IMID. Treat-
ment of IMID/EIM manifestations by introducing a second drug was
very successful in our cohort with an overall efficacy rate of 81%
(complete or partial improvement). This information from the largest
study available to date confirms that this strategy is realistic and
useful in IBD patients with uncontrolled IMID/EIM.
Our study has several strengths. First, our work differs from
previously published series by the large number of patients included,
particularly the 33 combinations for concomitant IMID/EIM, and the
longer follow‐up time. Second, all data, including significant adverse
events, were extracted and graded in a standardised way allowing a
more robust analysis. Lastly, our study is one of the first studies to
analyse in detail the indications, order‐of‐drug combinations and
prior exposure to treatment for each single combination. Indeed, a
successful combination with a naïve drug can be understood as a
simple response to that drug, whatever the context for the
combination.
We also acknowledge some weaknesses mostly due to the retro-
spective nature of the study. We were unable to identify benign in-
fections and mild infections not leading to hospitalisation. Therefore a
definitive answer regarding the infectious risk cannot be given. Details
of endoscopic scores (SES‐CD, MAYO scores) were lacking for some
procedures, and thus, a simplified endoscopic score was applied to
homogenise the data. Although the simplified endoscopic score is not
ideal, it was done by experts in IBD. Some follow up data on endoscopic
activityweremissingbut thesepatientswere identifiedas follows: 66%
T A B L E 6 IMID/EIM disease activity parameters at the start of combination and during combination in patients with active IMID/
EIM � active inflammatory bowel disease
IMID/EIM activity
At the start of combination (baseline) During combination
Group B + C
N = 33
Clinical assessmenta (n, %)
Quiescent – 9 (31)
Mild 1 (3) 12 (41)
Moderate 19 (66) 7 (24)
Severe 9 (31) 1 (3)




p‐value (binominal test) p < 0.0001
Steroids use (n, %)
No (n, %) 24 (72.7) 27 (81.8)
Yes (n, %) 9 (27.3) 6 (18.2)
Abbreviations: EIM, extra‐intestinal manifestation; IBD, Inflammatory bowel disease; IMID, immune mediated inflammatory disease.
aClinical assessment was unavailable for four combinations.
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had a clinical response, 34% did not show clinical improvement and 7%
underwent surgery. Lastly, although our cohort consisting of IBD pa-
tients suffering from active disease was large, there was some het-
erogeneity in terms of disease characteristics and prior exposure to
therapieswhich limits the accurate appraisal of clinical and endoscopic
efficacy. The question of efficacy should be answered through a pro-
spective trial with clinical, endoscopic and biologic evaluation at
various time points in a well‐defined IBD population.
CONCLUSION
In conclusion, this multicentre study suggests the efficacy of
combining two biologics or one biologic and a small molecule in pa-
tients with therapy‐refractory IBD and highlights the favourable ef-
ficacy for treating refractory EIM and IMID associated with IBD.
Infectious complications remain the main concern in this approach as
evidenced by our study. Combining biologics and small molecules
should be offered in IBD expert centres to highly selected patients
when no other therapeutic options nor access to molecules in
development are available. In the future, a better understanding of
the rationale for combination is needed to help clinician’s decision in
these difficult to treat populations.13
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